GKOS - Glaukos Corporation - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

6.035B

Cash

272.9M

Avg Qtr Burn

-15.22M

Short % of Float

4.98%

Insider Ownership

3.48%

Institutional Own.

-

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
travoprost-iDose® TR (IMPLANT) Details Primary open angle glaucoma , Eye disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Epioxa™ (Epi-on) Details Eye disease , Keratoconus	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
iDose TREX Details Eye disease , Primary open angle glaucoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
iLution Travoprost (GLK-311) Details Eye disease , Primary open angle glaucoma	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.